R R

What Is Transarterial Chemoembolization?

Transarterial chemoembolization is an image-guided treatment that delivers chemotherapy and embolic material directly into arteries feeding a liver tumor. It is commonly abbreviated TACE. The treatment exposes the tumor to a high local concentration of anticancer drug while reducing arterial blood flow that supports the tumor. TACE is most commonly used for selected hepatocellular carcinoma that is confined predominantly to the liver and is not being treated with curative resection, ablation, or transplantation.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Transarterial Chemoembolization?

Transarterial chemoembolization is an image-guided treatment that delivers chemotherapy and embolic material directly into arteries feeding a liver tumor. It is commonly abbreviated TACE. The treatment exposes the tumor to a high local concentration of anticancer drug while reducing arterial blood flow that supports the tumor. TACE is most commonly used for selected hepatocellular carcinoma that is confined predominantly to the liver and is not being treated with curative resection, ablation, or transplantation.

read more about transarterial chemoembolization ...

Copy this HTML:

Copy HTML Copied!

Why Is Transarterial Chemoembolization Performed?

TACE is a standard locoregional treatment for many patients with intermediate-stage hepatocellular carcinoma when liver function and performance status are suitable. It can also be used in selected patients as a bridge or downstaging treatment before liver transplantation or another therapy. Treatment decisions consider tumor number and size, portal-vein blood flow, liver function, cancer spread outside the liver, prior therapy, and overall health. Patients with severe liver dysfunction or disease that cannot be treated selectively can face more harm than benefit from embolization.

How Is Transarterial Chemoembolization Performed?

An interventional radiologist inserts a catheter through an artery in the groin or wrist and advances it under X-ray guidance into branches of the hepatic artery supplying the tumor. Angiography identifies tumor-feeding vessels and helps avoid nontarget arteries. Conventional TACE uses chemotherapy mixed with an oily contrast agent followed by embolic particles, while drug-eluting-bead TACE uses microspheres that carry and release chemotherapy while obstructing blood flow. Treatment is performed as selectively as possible to limit injury to healthy liver tissue.

What Is Recovery Like After Transarterial Chemoembolization?

Many patients develop postembolization syndrome with abdominal pain, fever, nausea, fatigue, or reduced appetite during the first several days. Blood tests are used to monitor liver function, blood counts, and other effects after treatment. Follow-up computed tomography or magnetic resonance imaging evaluates tumor response and determines whether additional TACE sessions or another therapy is needed. Recovery and repeat-treatment timing depend on symptoms, liver function, imaging response, and the overall cancer plan.

What Are the Risks and Complications?

Possible complications include postembolization syndrome, bleeding at the catheter site, infection, liver abscess, bile-duct injury, and contrast-related complications. Liver function can worsen after embolization, and severe hepatic decompensation is a major concern in patients with limited liver reserve. Embolic material or chemotherapy can rarely reach nontarget vessels and injure the stomach, gallbladder, pancreas, or other tissues. Kidney injury, vascular damage, or treatment-related death is uncommon but possible in high-risk patients.

Frequently Asked Questions About Transarterial Chemoembolization

What cancers are commonly treated with TACE?

TACE is most strongly established for selected hepatocellular carcinoma, although transarterial techniques can also be used in other liver-dominant tumors under specific circumstances.

What is postembolization syndrome?

It is a common temporary group of symptoms after embolization that can include abdominal pain, fever, nausea, fatigue, and reduced appetite.

What is the difference between conventional TACE and DEB-TACE?

Conventional TACE delivers chemotherapy with an oily carrier followed by embolic material, while drug-eluting-bead TACE uses microspheres that both obstruct blood flow and release chemotherapy.

Can TACE be repeated?

Yes. Repeat treatment can be used when imaging shows residual or recurrent tumor and liver function remains adequate for another procedure.

References

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. PubMed. https://pubmed.ncbi.nlm.nih.gov/37199193/. Date Accessed September 11, 2026.

Liver Cancer Treatment. National Cancer Institute. https://www.cancer.gov/types/liver/what-is-liver-cancer/treatment. Date Accessed September 11, 2026.

Hepatocellular Carcinoma Locoregional Therapies. American Association for the Study of Liver Diseases. https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/hepatocellular-carcinoma-locoregional-therapies. Date Accessed September 11, 2026.

Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma. PubMed. https://pubmed.ncbi.nlm.nih.gov/34805941/. Date Accessed September 11, 2026.

Complications of transarterial chemoembolization (TACE) in the treatment of liver tumors. PubMed. https://pubmed.ncbi.nlm.nih.gov/30082086/. Date Accessed September 11, 2026.